Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces it has entered into a global license and supply agreement with Sanofi SA (ADR) (NYSE:SNY) to utilize Captisol in …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta® (eltrombopag), a Novartis product, …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) partner Viking Therapeutics Inc (NASDAQ:VKTX) announced that it had closed its initial public offering (the “Viking IPO”) of 3,000,000 …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) partner Viking Therapeutics Inc (NASDAQ:VKTX) announced that it has priced its initial public offering of 3,000,000 shares of its …
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the appointment of Melanie J.
Ligand Pharmaceuticals Incorporated Inc. (NASDAQ:LGND) partner TG Therapeutics, Inc.
In a research report sent to investors yesterday, Deutsche Bank analyst Gregg Gilbert initiated coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy rating and …
In a research report published Thursday, Cantor analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ:LGND) and slightly raised her price target to $46 …
